APA

Cuesta A. M., Albiñana V., Gallardo-Vara E., Recio-Poveda L., de Rojas-P I., de Las Heras K. V. G., Aguirre D. T. & Botella L. M. (20201109). The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. : Scientific reports.

Chicago

Cuesta A M, Albiñana V, Gallardo-Vara E, Recio-Poveda L, de Rojas-P I, de Las Heras K Villar Gómez, Aguirre D T and Botella L M. 20201109. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. : Scientific reports.

Harvard

Cuesta A. M., Albiñana V., Gallardo-Vara E., Recio-Poveda L., de Rojas-P I., de Las Heras K. V. G., Aguirre D. T. and Botella L. M. (20201109). The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. : Scientific reports.

MLA

Cuesta A M, Albiñana V, Gallardo-Vara E, Recio-Poveda L, de Rojas-P I, de Las Heras K Villar Gómez, Aguirre D T and Botella L M. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. : Scientific reports. 20201109.